Core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg) - Scientific guideline

This guidance describes the information to be included in the summary of product characteristics for human normal immunoglobulins for intravenous administration.

Keywords: Intravenous immunoglobulin (IVIg), primary immunodeficiency syndromes, hypogammaglobulinaemia, primary immune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), Guillain Barré syndrome, Kawasaki disease, multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), myasthenia gravis exacerbations.

Current effective version

Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 6

AdoptedReference Number: EMA/CHMP/BPWP/94038/2007 Rev. 6 Corr.Legal effective date: 01/01/2022

Document history - Revision 6

Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 6

AdoptedReference Number: EMA/CHMP/BPWP/94038/2007 Rev. 6 Corr.Legal effective date: 01/01/2022

Overview of comments received on Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 Rev. 6)

Reference Number: EMA/30450/2021

Draft guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 6

Draft: consultation closedConsultation dates: 13/10/2020 to 13/01/2021Reference Number: EMA/CHMP/BPWP/94038/2007 Rev. 6

Document history - Revision 5

Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 5

AdoptedReference Number: EMA/CHMP/BPWP/94038/2007 Rev. 5Legal effective date: 01/01/2019

Overview of comments received on 'the guideline Core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 Rev. 5) - Revision 5

Reference Number: EMA/CHMP/BPWP/572924/2018

Draft guideline on core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg) - Rev.5

Draft: consultation closedConsultation dates: 01/01/2017 to 31/03/2017Reference Number: EMA/CHMP/BPWP/94038/2007 Rev. 5Summary:

This guideline describes the information to be included in the Summary of Product Characteristics (SmPC) for human normal immunoglobulins for intravenous administration.

Document history - Revision 4

Guideline on core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg) revision 4

AdoptedReference Number: EMA/CHMP/BPWP/94038/2007 Rev. 4Summary:

This guideline describes the information to be included in the Summary of Product Characteristics (SmPC) for human normal immunoglobulins for intravenous administration.

Draft concept paper on guideline on the clinical investigation of human normal immunoglobulin for intravenous administration and core summary of product characteristics

Draft: consultation closedConsultation dates: 01/08/2014 to 31/10/2014Reference Number: EMA/CHMP/BPWP/572805/2013Summary:

The current note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg, EMA/CHMP/BPWP/94033/2007 revision 2) and the core summary of product characteristics (SmPC) for human normal IVIg (CHMP/BPWP/94038/2007 revision 4) have been in operation since December 2000 and underwent a major revision process from 2006 to 2010. The question arises whether the guideline and the core SmPC should be updated to include chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy as being 'established indications'. Additionally, some international experts recommend that dosing in replacement therapy and in.immunomodulation should be re-evaluated, possibly with adjustment according to lean body weight.

Document history - Revision 3

Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) Rev. 3

AdoptedReference Number: EMA/CHMP/BPWP/94038/2007 rev. 3Legal effective date: 01/05/2011Summary:

This guideline (EMA/CHMP/BPWP/94038/2007 rev. 3) replaces guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) with reference number

CPMP/BPWP/859/95 rev. 2.

Overview of comments received on Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 rev. 3 formerly CPMP/BPWG/859/95 rev. 3)

Reference Number: EMA/CHMP/BPWP/375734/2010

Draft guideline on Core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (CPMP/BPWG/859/95 rev. 3)

Draft: consultation closedReference Number: CPMP/BPWG/859/95 Rev. 3

Document history - Revision 1

Concept paper on revision of: Note for Guidance on the Clinical Investigation of Human Normal Immunoglobulin for Intravenous Administration (IVIg) and on the Core SPC for Human Normal l Immunoglobulin for Intravenous Administration (IVIg) - Revision 1

Reference Number: EMEA/CHMP/BPWG/151426/2004